Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma — Rachael Anforth (2012) | RDL Network
Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma
Article 2012 en
Authors
RA
Rachael Anforth
TB
Tatiana Cristina Moraes Pinto Blumetti
RK
Richard Kefford
Abstract
1 min read
Administration of the mutant BRAF inhibitor dabrafenib is associated with induction of keratinocytic proliferation, which in some cases develops features of low-grade malignancy. Highly oncogenic HPV infection is unlikely to be a contributor to the formation of SCCs or verrucal keratoses.
Helen Rizos, Alexander M. Menzies, Gulietta M. Pupo, Matteo S. Carlino, Carina Fung, Jessica Hyman, Lauren E. Haydu, Branka Mijatov, Therese M. Becker, Suzanah C. Boyd, Julie R. Howle, Robyn P.M. Saw, John F. Thompson, Richard F. Kefford, Richard A Scolyer, Georgina V. Long
Helen Rizos, Alexander M. Menzies, Gulietta M. Pupo, Matteo S. Carlino, Carina Fung, Jessica Hyman, Lauren E. Haydu, Branka Mijatov, Therese M. Becker, Suzanah C. Boyd, Julie R. Howle, Robyn P.M. Saw, John F. Thompson, Richard F. Kefford, Richard A Scolyer, Georgina V. Long
James S. Wilmott, Hussein A. Tawbi, Johnathan A. Engh, Nduka Amankulor, Brindha Shivalingam, Hiya Banerjee, Ismael A. Vergara, Hansol Lee, Peter A. Johansson, Peter M. Ferguson, Philippe Saïag, Caroline Robert, Jean‐Jacques Grob, Lisa H. Butterfield, Richard A Scolyer, John M. Kirkwood, Georgina V. Long, Michael A. Davies
Discussion(0)
No comments yet. Be the first to comment.